The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology.
In vitro studies have provided little consensus on the kinetic abnormality underlying the myeloid expansion of chronic myelogenous leukemia (CML). Transplantation of human CML cells into non-obese diabetic mice with severe immunodeficiency disease (NOD/SCID mice) may therefore be a useful model. A CML cell line (BV173) and peripheral blood cells collected from CML patients in chronic phase (CP), accelerated phase (AP), or blastic phase (BP) were injected into preirradiated NOD/SCID mice. Animals were killed at serial intervals; cell suspensions and/or tissue sections from different organs were studied by immunohistochemistry and/or flow cytometry using antihuman CD45 monoclonal antibodies (MoAbs), and by fluorescence in situ hybridization (FISH) for the BCR-ABL fusion gene. One hour after injection, cells were sequestered in the lungs and liver, but 2 weeks later they were no longer detectable in either site. Similar short-term kinetics were observed using 51Cr-labeled cells. The first signs of engraftment for BV173, AP, and BP cells were detected in the bone marrow (BM) at 4 weeks. At 8 weeks the median percentages of human cells in murine marrow were 4% (range, 1 to 9) for CP, 11% (range, 5 to 36) for AP, 38.5% (range, 18 to 79) for BP, and 54% (range, 31 to 69) for BV173. CP cells progressively infiltrated BM (21%) and spleen (6%) by 18 to 20 weeks; no animals injected with the cell line or BP cells survived beyond 12 weeks. The rate of increase in human cell numbers was higher for BP (7.3%/week) as compared with CP (0.9%/week) and AP (0. 5%/week). FISH analysis with BCR and ABL probes showed that some of the human cells engrafting after injection of CP cells lacked a BCR-ABL gene and were presumably normal. We conclude that CML cells proliferate in NOD/SCID mice with kinetics that recapitulate the phase of the donor's disease, thus providing an in vivo model of CML biology.
Dazzi
F
F
Department of Haematology, Imperial College School of Medicine at Hammersmith Hospital, London, UK. f.dazzi@rpms.ac.uk
Capelli
D
D
Hasserjian
R
R
Cotter
F
F
Corbo
M
M
Poletti
A
A
Chinswangwatanakul
W
W
Goldman
J M
JM
Gordon
M Y
MY
D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics; D001752:Blast Crisis / Q000473:pathology; D001853:Bone Marrow / Q000473:pathology; D004273:DNA, Neoplasm / Q000235:genetics; D018450:Disease Progression; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006085:Graft Survival; D006801:Humans; D017403:In Situ Hybridization; D007700:Kinetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D015465:Leukemia, Myeloid, Accelerated Phase / Q000473:pathology; D015466:Leukemia, Myeloid, Chronic-Phase / Q000473:pathology; D008099:Liver / Q000473:pathology; D008168:Lung / Q000473:pathology; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D009360:Neoplastic Cells, Circulating; D014411:Neoplastic Stem Cells / Q000473:pathology / Q000637:transplantation*; D013047:Specific Pathogen-Free Organisms; D014018:Tissue Distribution; D014183:Transplantation, Heterologous
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D016044:Fusion Proteins, bcr-abl